Predictors of Mechanical Ventilation in Guillain–Barré Syndrome with Axonal Subtypes

ABSTRACT: Background: The early clinical predictors of respiratory failure in Latin Americans with Guillain–Barré syndrome (GBS) have scarcely been studied. This is of particular importance since Latin America has a high frequency of axonal GBS variants that may imply a worse prognosis. Methods: We studied 86 Mexican patients with GBS admitted to the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, a referral center of Mexico City, to describe predictors of invasive mechanical ventilation (IMV). Results: The median age was 40 years (interquartile range: 26–53.5), with 60.5% men (male-to-female ratio: 1.53). Most patients (65%) had an infectious antecedent (40.6% gastrointestinal). At admission, 38% of patients had a Medical Research Council (MRC) sum score <30. Axonal subtypes predominated (60.5%), with acute motor axonal neuropathy being the most prevalent (34.9%), followed by acute inflammatory demyelinating polyneuropathy (32.6%), acute motor sensory axonal neuropathy (AMSAN) (25.6%), and Fisher syndrome (7%). Notably, 15.1% had onset in upper limbs, 75.6% dysautonomia, and 73.3% pain. In all, 86% received either IVIg (9.3%) or plasma exchange (74.4%). IMV was required in 39.5% patients (72.7% in AMSAN). A multivariate model without including published prognostic scores yielded the time since onset to admission <15 days, axonal variants, MRC sum score <30, and bulbar weakness as independent predictors of IMV. The model including grading scales yielded lower limbs onset, Erasmus GBS respiratory insufficiency score (EGRIS) >4, and dysautonomia as predictors. Conclusion: These results suggest that EGRIS is a good prognosticator of IMV in GBS patients with a predominance of axonal electrophysiological subtypes, but other early clinical data should also be considered.

[1]  I. Estrada-Bellmann,et al.  SARS-CoV-2-associated Guillain-Barré syndrome: a descriptive and comparative analysis , 2021, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[2]  M. Varma,et al.  Neurological and Head/Eyes/Ears/Nose/Throat Manifestations of COVID-19: A Systematic Review and Meta-Analysis , 2021, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[3]  E. Piccione,et al.  Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review , 2021, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[4]  Y. Qi,et al.  Elevated cerebrospinal fluid levels of beta-2-microglobulin in patients with Guillain-Barré syndrome and their correlations with clinical features , 2021, Neurological Sciences.

[5]  E. Gómez‐Figueroa,et al.  Classic and overlapping Miller-Fisher syndrome: clinical and electrophysiological features in Mexican adults , 2021, Neurological Sciences.

[6]  R. Garg,et al.  Clinical Profile and Predictors of Mechanical Ventilation in Guillain-Barre Syndrome in North Indian Children , 2020, Journal of child neurology.

[7]  I. Sharawat,et al.  Predictors of unfavorable outcome in Guillain-Barre syndrome , 2020, Journal of Clinical Neuroscience.

[8]  J. Sejvar,et al.  The Brighton Collaboration case definition: Comparison in a retrospective and prospective cohort of children with Guillain‐Barré syndrome , 2020, Journal of the peripheral nervous system : JPNS.

[9]  G. Delgado-García,et al.  Electrophysiological subtypes and associated prognosis factors of Mexican adults diagnosed with Guillain-Barré syndrome, a single center experience , 2020, Journal of clinical neuroscience.

[10]  M. Stojanović,et al.  Disability and quality of life in Guillain-Barré syndrome – Longitudinal study , 2020, Journal of Clinical Neuroscience.

[11]  J. Sejvar,et al.  Zika Virus infection and Guillain-Barré syndrome in Northeastern Mexico: A case-control study , 2020, PloS one.

[12]  A. Zonderman,et al.  Nationwide study of therapeutic plasma exchange vs intravenous immunoglobulin in Guillain‐Barré syndrome , 2020 .

[13]  A. Zlotnik,et al.  Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS) , 2020, Journal of Clinical Neuroscience.

[14]  J. Sejvar,et al.  Guillain-Barré syndrome and antecedent cytomegalovirus infection, USA 2009–2015 , 2019, Neurological Sciences.

[15]  C. Serrati,et al.  Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study , 2019, Neurological Sciences.

[16]  Badrul Islam,et al.  Diagnosis and management of Guillain–Barré syndrome in ten steps , 2019, Nature Reviews Neurology.

[17]  Saira Abbas,et al.  Clinical Features Indicating the Need for Mechanical Ventilation in Patients with Guillain Barre Syndrome , 2019, Cureus.

[18]  J. Sejvar,et al.  Long-term outcomes of Guillain-Barré syndrome possibly associated with Zika virus infection , 2019, PloS one.

[19]  J. R. Rebello Pinho,et al.  Guillain–Barré syndrome—the challenge of unrecognized triggers , 2019, Neurological Sciences.

[20]  E. Granieri,et al.  Incidence study of Guillain-Barré syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up , 2019, Neurological Sciences.

[21]  I. Bozovic,et al.  Three-Year Follow-Up Study in Patients with Guillain-Barré Syndrome , 2018, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[22]  C. Green,et al.  Predictors of respiratory failure in patients with Guillain–Barré syndrome: a systematic review and meta‐analysis , 2018, The Medical journal of Australia.

[23]  H. Sentíes-Madrid,et al.  [Mortality associated with a diagnosis of Guillain-Barré syndrome in adults of Mexican health institutions]. , 2014, Revista de neurologia.

[24]  A. Uncini,et al.  Outcome and its predictors in Guillain–Barré syndrome , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[25]  Matthew Wise,et al.  Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis , 2011, Neuroepidemiology.

[26]  Hester F. Lingsma,et al.  Prediction of respiratory insufficiency in Guillain‐Barré syndrome , 2010, Annals of neurology.

[27]  E. Steyerberg,et al.  A clinical prognostic scoring system for Guillain-Barré syndrome , 2007, The Lancet Neurology.

[28]  R. Porcher,et al.  Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study , 2006, The Lancet Neurology.

[29]  S. Shafqat,et al.  Guillain–Barré syndrome in Pakistan: similarity of demyelinating and axonal variants , 2006, European journal of neurology.

[30]  N. Thomas Diagnosis and management of Guillain–Barré syndrome , 2005 .

[31]  J. Raphaël,et al.  [Guillain-Barré syndrome]. , 2005, La Revue du praticien.

[32]  S. Kumar Mechanical ventilation in Guillain-Barre syndrome. , 2003, Neurology India.

[33]  E. Wijdicks,et al.  Anticipating mechanical ventilation in Guillain-Barré syndrome. , 2001, Archives of neurology.

[34]  J. Zhang,et al.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. , 1998, JAMA.

[35]  H. Hartung,et al.  Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome , 1998, Annals of neurology.

[36]  C. Bolton,et al.  Respiratory electrophysiological studies in Guillain-Barré syndrome. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[37]  J. Meulstee,et al.  Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. , 1996, Neurology.

[38]  D. Cornblath,et al.  Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.

[39]  R. Hughes,et al.  CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY , 1978, The Lancet.